Improving Lives, Globally

We created Anji to improve the performance of asset-centric biopharmaceutical companies. We do this by:
  • Picking targets with strong human evidence and clear path to value
  • Unlocking value through clinical proof-of-concept
  • Designing comprehensive and capital-efficient clinical development programs which maximize the exit optionality for each asset
The result is a well-diversified and renewable product pipeline that can deliver accessible medicines to millions of patients around the globe.

This Is Where Science Gets Done

Anji is an asset-centric company built to rapidly pursue well-validated drug targets and improve the lives of patients everywhere. We recently completed a multinational Phase 2 proof-of-concept study for ANJ908 in chronic idiopathic constipation. Our Phase 3 program to bring ANJ900 to patients with type 2 diabetes and advanced chronic kidney disease is on track to deliver results in 2024.

Building Bridges to
Life-Changing Medicines

Our name was inspired by the Anji Bridge (Zhaozhou Bridge), one of the oldest stone-arch bridges in the world. Anji translates to “safe crossing” and “to aid those in need.” Our biotech company bridges science and cultures to create safe and effective medicines for patients who need them most. Because building bridges is what we do.

For Patients

We’ve provided additional information and resources to untangle diseases like chronic constipation and type 2 diabetes with chronic kidney disease.

For partnerships, investment opportunities, or to learn more about our work, contact us.